R & D transformation of pharmaceutical giants: from competition to cooperation

Source: forbes.cn three years ago, US health officials suggested that pharmaceutical giants jointly develop treatment drugs rather than compete with each other At that time, these companies all said they could not accept it As we all know, pharmaceutical industry is one of the most competitive and self-protection fields Pharmaceutical giants will apply for patents for all aspects of drugs, will fight back against opponents who infringe their own interests, and will launch a price war to block competitors when the patent expires But now, in terms of gene research and specific drugs, several pharmaceutical giants around the world will lift their defenses and share their most conservative assets with their peers, aiming to develop therapeutic drugs faster Last week, the National Institutes of Health announced that 10 companies, including Bristol Myers Squibb, Pfizer, GlaxoSmithKline and Eli Lilly, had been mobilized to conduct a five-year study Pharmaceutical giants have collected data, including even some drug molecules that have applied for patents Later, Merck, who is also involved in the project, quickly said it would work with Pfizer, Amgen and Incyte to improve a new anti-tumor drug that Merck is developing The NIH study began in 2011, and since then, NIH president Francis Collins has been urging pharmaceutical companies to cooperate "This shift seems quite dramatic compared to the extremely competitive model of the past, and it took some time to get there," he said From the beginning to the end, a large part of the relevant discussions revolve around the question whether it is beneficial for pharmaceutical giants to do so? " "No matter how big a pharmaceutical giant is, no matter what disease it's targeting, it can't monopolize all those exciting drugs," said mace Rosenberg, chief medical officer of Pfizer's anti-tumor business Looking back, maybe that's why we haven't been able to make more progress in treating some diseases? Is it because we can only focus on one factor at a time? " NIH's $230 million collaborative research project aims to find new drugs for the causes of Alzheimer's, type 2 diabetes, rheumatoid arthritis and lupus "Although scientists have provided guidance in these areas, it seems that no pharmaceutical giant can seize these opportunities on its own, at least not as well as they expected," Collins said